Mirum’s brelovitug meets primary endpoint in second phase 3 trial
Mirum Pharmaceuticals (MIRM) reported that brelovitug met the primary endpoint in the Phase 3 AZURE-4 trial for chronic hepatitis delta virus, with 59% and 44% of patients achieving the combined endpoint in the two treatment arms. The drug has FDA Breakthrough Therapy and Orphan Drug Designations. Mirum plans to submit a Biologics License Application to the FDA in the first half of 2027.
How this was made
The 30-second read
Why it matters
The trial success positions Mirum for a potential FDA BLA, likely driving share price appreciation and attracting partnership interest.
Market read
First‑report Phase 3 data for a rare‑disease therapy; high relevance for biotech investors.
What to watch
The trial enrolled only 113 patients; larger Phase 3 data may be needed to confirm efficacy.
Background
Mirum is a Nasdaq‑listed biotech developing the first therapy for chronic hepatitis delta virus, a disease with no approved treatments.
Ticker impact
Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 trial met the primary endpoint, showing 59% and 44% response rates for two dosing regimens.
upward pressure as the market prices in the trial success and upcoming BLA filing.
Phase 3 success is a material catalyst for a biotech with no approved HDV therapy; the company plans a BLA in H1 2027.
Market effects
May boost sentiment for hepatitis delta and broader antiviral biotech sector.
US and European markets could see modest gains in biotech indices.
Limited to investors focused on rare‑disease therapeutics.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the rally could be short‑lived.
Key entities
- companyMirum Pharmaceuticals Inc.
Developer of brelovitug, a monoclonal antibody for HDV.
